A BS TRACT: Objective: Real-life observational report of clinical efficacy of bilateral subthalamic stimulation (STN-DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD). Methods: In this prospective, multicenter, international, reallife cohort observation study of 173 PD patients undergoing STN-DBS (n = 101), IJLI (n = 33), or APO (n = 39) were followed-up using PDQuestionnaire-8, NMSScale (NMSS), Unified PD Rating Scale (UPDRS)-III, UPDRS-IV, and levodopa equivalent daily dose (LEDD) before and 6 months after intervention. Outcome changes were analyzed with Wilcoxon signed-rank or paired t test when parametric tests were applicable. Multiple comparisons were corrected (multiple treatments/scales). Effect strengths were quantified with relative changes, effect size, and number needed to treat. Analyses were computed before and after propensity score matching, balancing demographic and clinical characteristics. Results: In all groups, PDQuestionnaire-8, UPDRS-IV, and NMSS total scores improved significantly at follow-up.
Levodopa equivalent daily dose was significantly reduced after STN-DBS. Explorative NMSS domain analyses resulted in distinct profiles: STN-DBS improved urinary/ sexual functions, mood/cognition, sleep/fatigue, and the miscellaneous domain. IJLI improved the 3 latter domains and gastrointestinal symptoms. APO improved mood/ cognition, perceptual problems/hallucinations, attention/ memory, and the miscellaneous domain. Overall, STN-DBS and IJLI seemed favorable for NMSS total score, and APO favorable for neuropsychological/neuropsychiatric NMS and PDQuestionnaire-8 outcome.
Conclusions: This is the first comparison of quality of life, nonmotor. and motor outcomes in PD patients undergoing STN-DBS, IJLI, and APO in a real-life cohort. Distinct effect profiles were identified for each treatment option. Our results highlight the importance of holistic nonmotor and motor symptoms assessments to personalize treatment choices. © 2019 International Parkinson and Movement Disorder Society Key Words: Apomorphine; Deep brain stimulation;
Intrajejunal levodopa infusion; Nonmotor symptoms; Quality of life Dyskinesia and motor fluctuations present major challenges in the long-term treatment of Parkinson's disease (PD). In the advanced stages of PD, these motor complications may be insufficiently controlled by oral medication regimens and require device-aided therapeutic strategies. The following 3 well-established, safe, and effective invasive treatments are available to improve quality of life (QoL), motor, and nonmotor symptoms (NMS): (1) deep brain stimulation of the subthalamic nucleus (STN-DBS) or other targets, (2) intrajejunal levodopa infusion (IJLI), and (3) apomorphine infusion (APO). [1] [2] [3] [4] [5] These clinical aspects of PD have only been investigated in 1 comparative study of IJLI and APO, 5 and no head-to-head studies are available comparing all 3 therapeutic strategies. Therefore, the present work is the first observation of the differential treatment effects of STN-DBS, IJLI, and APO in patients with advanced PD. Based on previous studies of our group, 4, 5 we hypothesized that these 3 treatments offer distinct effect profiles on QoL, motor, and nonmotor aspects of PD.
Methods Study Design and Ethical Approval
This was a prospective, nonrandomized, observational, multicenter, international, real-life cohort observation with a 6-month follow-up period. 4, 5 Patients reported here were enrolled in five movement disorders centers (Cologne, London, Venice, São Paulo, and Ljubljana). These centers were chosen based on their experience in using motor and nonmotor scales, their expertise in surgical and device-aided medical therapies, and their ability to provide these treatment options under one roof without healthcare system restrictions/prerequisites. The study was carried out in accordance with the Declaration of Helsinki and authorized by the local ethics committees (master for DBS: Cologne, 12-145; German Clinical Trials Register, 6735; master for infusion therapies: United Kingdom, NRES SouthEast London REC3, 10/H0808/141, 10084). All patients gave written consent prior to study procedures.
Patients
PD diagnosis was based on British Brain Bank criteria. Patients were screened for bilateral STN-DBS, IJLI, and APO according to the International PD and Movement Disorders Society and national neurological society guidelines. 6, 7 Eligibility for invasive PD treatment required the absence of clinically relevant neuropsychiatric and cognitive disturbances in multidisciplinary assessments by expert neuropsychologists and neuropsychiatrists as well as a satisfactory response of motor impairment in levodopa or apomorphine challenge tests (>30% improvement of UPDRS-III). Per clinical routine, the choice of advanced treatment option was based on assessments by clinical teams and discussions with patients to ensure informed choices according to patients' wishes. To guarantee informed choices, effect profiles of surgical and device-aided medical therapies were discussed with patients based on these assessments prior to intervention. Patients were also informed about the possible adverse effects profiles of treatments based on the experience of multidisciplinary teams and on previous studies. 1, 2, 8 For example, we typically recommended APO when patients preferred no surgery, IJLI when dopamine agonists were not well tolerated and stereotactic surgery was not possible or not wished, and STN-DBS when medication requirements were very high. On the other hand, based on previous studies, we advised against STN-DBS if neuropsychological impairment was clinically relevant. 9 Patients were included consecutively before they underwent advanced therapy. Patients who were concomitantly treated or switched between these therapies were excluded from statistical analyses.
Clinical Assessment
Clinical assessments were carried out at preoperative baseline (MedON/MedOFF) and at 6-month follow-up after surgery (MedON-StimON) with the following scales:
1. Motor disorder: UPDRS-III, UPDRS-IV, and Hoehn and Yahr scale were used to investigate motor impairment, complications, and global motor dysfunction. 10 2. The therapeutic medical regimen was recorded calculating the levodopa equivalent daily dose (LEDD) according to the method of Tomlinson et al. 11 3. The PD Questionaire-8 (PDQ-8) has previously been used in patients with PD and STN-DBS, 12,13 APO, and IJLI. 5 The PDQ is recommended for QoL assessments by the Movement Disorders Society Scales Committee 14 and has been commonly used studies on invasive therapies of advanced PD. 1, 2, 15 The results are reported as PDQ-8 Summary Index (PDQ-8 SI) to ease the interpretation of our results and comparisons with other studies. 4. The NMSScale (NMSS) was used to survey the following nine domains of NMS: cardiovascular, sleep/fatigue, mood/cognition, perceptional problems/hallucinations, attention/memory, gastrointestinal, urinary, sexual function, and miscellaneous, which consists of items for pain, inability to smell or taste, weight change, and excessive sweating. 16 
Adverse Events
Adverse events (AE) were extracted from databases and patient files and coded according to the Medical Dictionary for Regulatory Activities (version 14.1). AE were classified as mild, moderate, or severe AE or serious AE (SAE) consistent with previously published criteria (see Supporting Information document, section 1.1).
17,18

Statistical Analysis
The normality of distribution was assessed with the Shapiro-Wilk test. Differences of baseline characteristics between the three treatment groups were analyzed with Kruskal-Wallis tests or 1-way ANOVA analysis of variance if parametric tests were applicable. Outcome changes from baseline to follow-up of each group were tested with Wilcoxon signed-rank or pairedsamples t tests. Benjamini-Hochberg correction was used to account for multiple comparisons because of the use of multiple tests and three treatment options. All P values presented were adjusted to the significance threshold P < .05 unless stated otherwise. All statistical tests were two-tailed. 19 KruskalWallis test and 1-way analysis of variance were analyzed for test change scores. Furthermore, numbers needed to treat were calculated (1/% of patients improving >1/2 SD Test baseline ). Furthermore, the relationship of PDQ-8 SI and NMSS total and domain scores was explored with Spearman correlations.
As this was an analysis of observational, real-life data, we additionally used propensity score matching to minimize selection bias and increase causal inference. The aim of employing this method was to find a subcohort of patients undergoing STN-DBS, APO, and IJLI treatment with well-balanced demographic and baseline clinical characteristics between treatment groups. Propensity score matching methodology is explained in detail in the supplementary material (see Supporting Information document, section 1.2) .
To analyze QoL outcomes at all responder levels, in accordance with the Food and Drug Administration's recommendations for analyses of patient-reported outcomes, 20 cumulative distribution functions were computed for PDQ-8 SI. The proportion of patients who improved more than a designated threshold (≥1/2 SD PDQ-8 SI baseline ) 5, 21 was compared between treatment groups. Anonymized data will be shared by request from any qualified investigator.
Results
A total of 173 patients (104 men) with PD undergoing bilateral STN-DBS (n = 101), IJLI (n = 33), or APO (n = 39) were included in the statistical analyses. Patients in the infusion therapy groups were enrolled consecutively between January 2013 and December 2016 and in the STN-DBS group between August 2013 and December 2016. Of the 225 patients assessed as eligible for this study, 14 patients declined study participation, 22 patients underwent DBS in the Globus pallidus interna (GPi) or ventral indermediate nucleus of the thalamus (ViM), 9 patients switched from APO to IJLI, 1 patient who was started on APO had concomitant DBS therapy, and 6 patients were excluded for other reasons (none stopped advanced treatment before 6-month follow-up). The 173 patients in the final analysis were aged 62.3 years AE9.5 with 12.1 years AE5.3 disease duration. The median MedON Hoehn and Yahr was 2.5 (interquartile range 2.0-3.0).
Baseline Characteristics in the Original Cohort
Comparing baseline parameters of the three groups (see Table 1 ), we observed a significantly shorter disease duration in the STN-DBS group than both infusion therapies (P < .001). Also, less severe impairment was found for clinical parameters in the STN-DBS group than both infusion therapy groups in the following scales: UPDRS-III (P = .011), Hoehn and Yahr scale, UPDRS-IV, and NMSS total scores (all P ≤ .001). Furthermore, lower baseline impairment was found for the STN-DBS when compared with the IJLI group for PDQ-8 SI (P = .001), NMSS cardiovascular, gastrointestinal, and miscellaneous domains (all P ≤ .011). The latter was driven by the item for excessive sweating (STN-DBS, 2.8 AE 3.4; IJLI, 4.2 AE 3.0; APO, 5.6 AE 4.4; F 2,144 = 8.104; P = .001; post-hoc Mann-Whitney U test: P < .001). Lower baseline impairment was also observed for the STN-DBS when compared with the APO group for the NMSS mood/cognition and attention/memory domains (both P ≤ .001). No significant difference was observed for the dyskinesia/motor fluctuations ratio (UPDRS-IV subitems) between treatment groups. Baseline characteristics of the matched subcohort are provided in the supplementary material (see Supporting Information document, section 2.2).
Changes of Outcomes at Follow-Up in the Original Cohort
In the STN-DBS, IJLI, and APO groups, PDQ-8 SI, UPDRS-IV, and NMSS improved significantly at follow-up (all P < .010; see Table 2 ). As expected, LEDD was significantly reduced by approximately 52% in the STN-DBS group (P < .001) and remained stable in infusion therapies. This difference in LEDD change was significant (P < .001, Kruskal-Wallis test). There was no significant difference between continuous infusion times for IJLI (15.4 hours/day AE1.3) and APO (15.4 hours/day AE2.6; P = .907; no 24-hour infusions in both groups). Hoehn and Yahr score improved significantly in the IJLI and APO groups (both P < .005). No significant difference was found for treatment effects on dyskinesia/motor fluctuations ratios between treatment groups (P > .05).
Post-hoc analyses of NMSS domain scores revealed differential effects for the 3 treatment groups (see Fig. 1 ): In the STN-DBS group, significant beneficial effects were observed for sleep/fatigue (P < .001), mood/cognition (P = .010), perceptual problems/hallucinations (P = .015), urinary symptoms (P = .001), sexual functions (P = .020), and the miscellaneous domain (P < .001), which was driven by the items pain (baseline, 2.2 AE 3.6; follow-up, 1.4 AE 2.5; P = .047), inability to smell or taste (baseline, 2.8 AE 3.5; follow-up, 1.5 AE 2.8; P < .001), and excessive sweating (baseline, 2.7 AE 3.3; follow-up, 0.9 AE 2.0; P < .001). In the IJLI group, at follow-up, we found a significant improvement of sleep (P = .016), mood/cognition (P = .010), gastrointestinal symptoms (P = .027), and the miscellaneous domain (P = .031), which was driven by the inability to taste and smell (baseline, 4.8 AE 3.5; follow-up, 3.2 AE 3.7; P = .016). In the APO group, we observed significant improvement of mood/cognition (P = .009), perceptual problems/hallucinations (P = .014), attention/memory (P = .009), and the miscellaneous domain (P = .002), which was driven by weight change (baseline, 1.8 AE 3.5; follow-up, 0.3 AE 1.2; P = .004) and excessive sweating (baseline, 5.7 AE 4.4; follow up, 3.1 AE 3.9; P = .002).
Effect sizes were large for UPDRS-IV and moderate for PDQ-8 SI in all three groups (see Table 3 ). In the STN-DBS group, effect sizes were large for LEDD and moderate for NMSS total score. In the IJLI and APO groups, effect sizes were moderate for NMSS total score, PDQ-8 SI, and Hoehn and Yahr scale and small for LEDD. Kruskal-Wallis tests and 1-way ANOVA analysis of variance did not detect additional intergroup differences. Number needed to treat results were favorable for bilateral STN-DBS regarding LEDD reduction and UPDRS-III, for IJLI regarding UPDRS-IV and NMSS total score, and for APO regarding Hoehn and Yahr scale and PDQ-8 SI (see Supporting Information Table e-1). Explorative Spearman correlations showed a significant association between improvements of PDQ-8 SI and mood/cognition domain for all treatments (ρ STN-DBS = 0.305, ρ IJLI = 0.526, ρ APO = 0.429, all P ≤ .007; see Supporting Information Table e-2). In addition, in the APO group, a significant correlation was found between PDQ-8 SI and attention/memory (ρ = 0.429, P = .007) and cardiovascular domains (ρ = 0.375, P = .020). Beneficial effects on urinary symptoms in the STN-DBS group (ρ = 0.245, P = .015) and on sleep/fatigue in the IJLI group (ρ = 0.378, P = .036) were also significantly correlated to improvements of PDQ-8 SI. Cumulative distribution curves indicated that for the STN-DBS, IJLI, and APO groups, approximately 56%, 58%, and 62% of patients experienced an improvement of PDQ-8 SI greater than the designated threshold, respectively (≥1/2 SD PDQ-8 SI baseline ; see Supporting Information Figure e-1a). Changes of outcomes at follow-up in the matched subcohort are provided in the Supporting Information (see Supporting Information document, section 2.3). Comparing relative changes and effect sizes (see Table 3 ) of STN-DBS to infusion therapies, we observed more beneficial effects of STN-DBS on sleep/fatigue, perceptual problem/hallucinations, urinary symptoms, and sexual functions and weaker effects on attention/memory.
Adverse Events
AE and SAE are reported in Table 4 . In the immediate postoperative period, nonserious AE were more frequently observed in the IJLI group, in particular, abdominal pain and gastrointestinal symptoms. A detailed report of individual SAE is provided in the Supporting Information (see Supporting Information document, section 2.1).
Discussion
In this prospective, nonrandomized, multicenter, international, real-life cohort observation including 173 patients with advanced PD, we observed significant beneficial effects of bilateral STN-DBS, IJLI, and APO on global NMS burden and specific aspects of NMS. This is the first report of motor, nonmotor, or QoL outcomes comparing these three invasive treatment options in PD in a real-life population. Although our study was not a randomized, blinded, triple-dummy study in a well-selected Raw P values are presented for comparisons of STN-DBS, IJLI, and APO regarding demographic and baseline clinical outcome parameters. The UPDRS-III, UPDRS-IV and H&Y range from 0 (no impairment) to 108, 23, and 5.0, respectively (maximum impairment). The PDQ-8 SI ranges from 0 (no impairment) to 100 (maximum impairment). The NMSS ranges from 0 (no impairment) to 360 (maximum impairment). All scales were assessed preoperatively in population (such a study is complicated for logistic and economical reasons and unlikely to take place comparing all three therapies), it represents effects of these treatments as they can be observed in clinical pratice and as such we believe the data has real clinical impact.
Motor Disorder
As reported by previous studies, motor complications improved in STN-DBS, IJLI, and APO groups. 1, 5, 22 As expected, LEDD was significantly reduced by approximately 52% in the STN-DBS group, 1 whereas no significant changes were found in infusion therapy groups. 2, 23 Furthermore, as expected, we found no significant changes of UPDRS-III between preinterventional MedON and postinterventional MedON(/StimON) for all three groups. 1, 2, 24 Our results also confirm studies that reported an improvement of ON-state Hoehn and Yahr scale for STN-DBS, 25 IJLI, 26 and APO. 27 Based on 
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dyskinesia/motor fluctuation ratios, treatments were chosen independently from these motor complication profiles.
NMS
In accordance with previous studies, we observed an improvement of global NMS burden in patients who underwent STN-DBS, [28] [29] [30] IJLI, 22 and APO. 5 Considering the relative changes and effect sizes, IJLI and STN-DBS seemed to be favorable over APO regarding the improvement of NMSS total score. Number needed to treat calculated to appraise the clinical relevance of these statistically significant results indicated that all three therapies are advantageous, with a slightly favorable result for IJLI.
Exploring specific NMS aspects, consistent with previous studies, we observed no beneficial effect of APO on cardiovascular symptoms. 5, 31 However, the significant correlation between NMSS cardiovascular and PDQ-8 SI improvements highlights the clinical importance of orthostatic hypotension as a frequently observed AE. Confirming previous studies, we observed beneficial effects of STN-DBS 32 and IJLI 22 on subjective sleep/fatigue symptoms, whereas no significant improvement was found for APO. This may be explained by more frequent daytime sleepiness for APO. In contrast to a previous study of our group, which reported a beneficial effect of APO on sleep symptoms, in the present study continuous nocturnal dopaminergic stimulation provided by a transdermal application of rotigotine was not initiated between baseline and follow-up visits in any patient. Consistent with previous studies that reported beneficial effects of STN-DBS and infusion therapies on neuropsychiatric symptoms, such as anxiety and depression, we found an improvement of the corresponding NMSS domain for all three treatment options. 5, [33] [34] [35] Furthermore, also confirming previous studies, APO treatment resulted in a significant reduction of perceptual problems/hallucinations, 8 which may result from its piperidine moiety and 5-HT2A serotonin receptor antagonist effect. 36 As reported previously, APO reduced perceptual problems/hallucinations to a greater extent than One patient admitted to a psychiatric department after suicide attempt (resolved without sequelae). One patient with infection at the IPG site required reimplantation (resolved with minor scarring). Three patients with impaired wound healing at the IPG site required surgical revision (1 case resolved with minor scarring, 2 cases without sequelae). One patient underwent required surgical revision (resolved without sequelae). One patient with hardware malfunction of a lead extension required surgical revision (resolved without sequelae). One patient required surgery for a benign prostate adenoma, unrelated to PD (resolved without sequelae). One patient with intestinal tube dislocation required hospitalization (resolved without sequelae). One patient with an infection of the stoma site required intravenous antibiotic treatment (resolved without sequelae). Two patients with impaired wound healing at stoma site required prolonged hospitalization (1 resolved with minor scarring, 1 resolved without sequelae).
IJLI. 5 The significant improvement of perceptual problems/ hallucinations in the STN-DBS group might be explained by the considerable postoperative LEDD reduction as described in previous studies. 37 Future studies including patients with NMS caused by high dopaminergic medication dosages are required. The improvement of attention/memory domain by APO observed here has also been reported previously. 31 However, there are also conflicting results from studies that have reported a worsening of attention under APO treatment, 38 and further studies are needed to investigate this issue. In addition, the present study confirms the observation of a significant improvement of gastrointestinal symptoms under IJLI therapy, which was reported by Antonini and colleagues 22 in the GLORIA study. The beneficial effects of STN-DBS on urinary symptoms 39 and sexual function 40 have previously been described. Furthermore, our results are consistent with previous studies that reported an improvement of the miscellaneous NMSS domain for STN-DBS, 4 IJLI, 22 and APO. 5, 31 The present work confirms previous STN-DBS studies that observed an improvement of pain, 41 olfactory symptoms, 42 and excessive sweating. 4 To our knowledge, this is the first report of beneficial effects of IJLI on subjective olfactory symptoms and of APO on excessive sweating and weight change.
One has to acknowledge that NMS are defined by exclusion and result from structural and functional changes in multiple brain networks and an associated multineuropeptide dysfunction. 43 The heterogeneity of pathomechanisms is one of the corner stones of the clinical heterogeneity observed in patients and provides a rationale for a differential treatment of NMS by surgical and device-aided medical therapies. 44 Therefore, we here advocate comprehensive motor and nonmotor assessments using validated, well-established, and pragmatic instruments as in the present study to identify which route of treatment is best suited for patients' personal profiles of nonmotor and motor symptoms. Effectively treating nonmotor as well as motor symptoms is important, in particular, as specific NMS, such as mood, cognition, and sleep, and NMS overall burden seem to have a higher relative importance for QoL. 45 
QoL
Based on a greater relative change, larger effect size, and smaller number needed to treat, we observed an advantageous effect of APO on QoL in our real-life cohort.
In the STN-DBS group, QoL improved by approximately 27% in the STN-DBS group in the original cohort, which is well within the range reported by previous randomized controlled trials. 1 In the matched subcohort, relative change decreased to approximately 17%. This effect is possibly based on the matching procedure that in the STN-DBS group resulted in older age, longer disease duration, and more severe baseline impairment in all clinical scales after matching. Our observation of an approximately 21% improvement of QoL in the IJLI group closely resembles the results from previous observational real-life studies. 46 However, a randomized, double-blind, double-dummy trial by Olanow and colleagues 2 indicates that in carefully selected cohorts of randomized controlled trials, QoL improvement may be considerably higher, as a 34% improvement was reported in this study. For APO, PDQ-8 improvement at the 6-month follow-up reported in the literature varies widely and ranges between 11.3% 3 and 41.9%. 31 Our current results are within this range, reported previously in observational studies, and resemble the findings of an approximately 30% improvement previously reported. 5 The underlying factors for the seemingly greater QoL improvement by APO in our cohort seems to be not dependent on motor outcomes that were more effectively controlled in the IJLI and STN-DBS groups. APO was mainly beneficial for neuropsychological and neuropsychiatric NMS domains, and this was significantly correlated to an improvement of QoL in our cohort. The relative importance of neuropsychological and neuropsychiatric NMS for QoL has previously been described in the general PD population. 45 
Adverse Events
Overall, SAE frequencies were lower in the STN-DBS group than in infusion therapy groups. Nonserious AE were more frequently observed in the IJLI group, mainly because of abdominal pain and gastrointestinal symptoms in the immediate postoperative phase. As the NMSS assesses symptoms during the previous 4 weeks, these gastrointestinal AE did not affect follow-up scores. In the STN-DBS group, dysarthria was more frequently observed. In the APO group, daytime sleepiness and orthostatic hypotension occurred more frequently. These AE profiles are consistent with previous studies. 8, 22, 47 Overall, moderate and severe nonserious AE were observed more frequently in infusion therapies than in STN-DBS. The short follow-up period in our study may explain the relatively low number of AE/SAE in the STN-DBS group when compared with previous STN-DBS studies. 17 
Differential Treatment Choices
As a general trend in the STN-DBS group, patient selection resulted in the lowest mean age at intervention, shortest disease duration, and least impairment for baseline clinical outcome parameters. Consistent with previous studies that have identified the relative importance of these factors, 13, 15, 18 in this highly selected group, improvements were observed for QoL, motor, nonmotor outcomes. As mentioned previously, our results indicate that the beneficial effects of STN-DBS may be particularly favorable if a reduction of dopaminergic medication may result in an improvement of specific nonmotor outcomes. In contrast to this group, demographic and baseline clinical parameters were highest in the IJLI group, and our results indicate that this a good treatment option for patients with very high motor and nonmotor burden of PD. To better understand which factors guided the differential treatment choice between APO and STN-DBS, one may highlight higher baseline neuropsychological and neuropsychiatric impairments in the APO group and the robust treatment effects that correlated with an improvement of QoL.
Limitations
The present work has several limitations. Although the cohort size of the overall study population (n = 173) is one of the largest in studies of its kind, specific treatment groups (STN-DBS, n = 101; IJLI, n = 33; and APO, n = 39) were relatively small and further prospective studies are required to confirm these findings. The multicenter design of the present study is likely to reduce systematic bias caused by single center studies. We did not conduct blinded assessments of clinical outcomes and because of the design of our database as a prospective, observational study, only clinical ON states (MedON/StimON) were recorded. We were interested in patients' real-life experiences of NMS and their relationship with QoL outcomes and employed scales that assess NMS and QoL during the previous month. Therefore, these scales reflect a combination of ON and OFF states 4 and are not feasible to assess nonmotor fluctuations. Furthermore, the followup period of 6 months was short. Long-term studies indicate high discontinuation rates in the first 5 to 6 years of IJLI and APO treatment. The reasons may be side-effects or waning therapeutic effects or because infusion therapies require the motivation for daily care. 8, 48 In this context, STN-DBS may provide more reliable long-term beneficial effects in a large proportion of patients, and comparative studies with a longer follow-up period are needed. To help the interpretation of our results, Cohen's effect sizes were calculated to classify clinical responses into small, moderate, and large. Although in the infusion groups confidence intervals of effect sizes were wide because of the relatively small group sizes, this approach was chosen because an alternative method, the minimal clinically important difference, 49 to our knowledge, has not been reported for the NMSS and its domains yet. Furthermore, limitations of propensity score matching are discussed in the Supporting Information (see Supporting Information document, section 3).
Conclusion
This is the first report of motor, nonmotor, and QoL outcomes in patients with PD undergoing bilateral STN-DBS, IJLI, and APO treatment in a real-life observational design. We found beneficial effects of all three treatment options on global NMS burden and specific aspects of NMS. STN-DBS improved urinary and sexual functions, mood/cognition, sleep/fatigue, and the miscellaneous domain. IJLI improved the three latter domains and gastrointestinal symptoms. APO improved mood/cognition, perceptual problems/hallucinations, attention/memory, and the miscellaneous domain. Overall, STN-DBS and IJLI seemed favorable for total NMS burden. APO particularly improved neuropsychological and neuropsychiatric NMS domains and, significantly related to this, seemed favorable for QoL improvement. This study highlights the importance of holistic assessments of motor as well as nonmotor aspects of PD that could provide a means to personalize treatment options to patients' individual PD profiles.
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